Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Chronic Corticosteroid Therapy Clear all
Completed Phase 3 Interventional Results available

S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps

NCT02291549
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
S8 Sinus Implant, Mometasone furoate nasal spray, Sham
Drug · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Birmingham, Alabama • Irvine, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Results available

Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis

NCT05868577
View directory record Official record
Conditions
Chronic Plantar Fasciitis
Interventions
Corticosteroid injection (CSI) with local anesthetic (LA), Local anesthetic (LA) with Saline injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis

NCT03072381
View directory record Official record
Conditions
Chronic Lateral Epicondylosis
Interventions
Platelet Rich Plasma - Group 1, Corticosteroid Control - Group 2
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional

Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population

NCT01382771
View directory record Official record
Conditions
Low Back Pain
Interventions
Intra-articular corticosteroid injection, Intra-articular saline injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT04200365
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Itacitinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Denver, Colorado • Nashville, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

NCT00054613
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Little Rock, Arkansas • Gainesville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)

NCT01009294
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Ataluren, Chronic Corticosteroid Therapy
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional

TPO-Mimetic Use in Children for Hematopoietic Failure

NCT04478227
View directory record Official record
Conditions
Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions
Romiplostim
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
0 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

NCT02841995
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Belumosudil (KD025)
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

NCT00771446
View directory record Official record
Conditions
Acute Hepatitis, Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
19 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 3, 2026, 6:56 PM EDT
Withdrawn No phase listed Observational

Oral Steroid Treatment for Chronic Rhinosinusitis

NCT01255683
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral corticosteroid taper
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting No phase listed Observational

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

NCT06659029
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628
View directory record Official record
Conditions
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Interventions
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 76 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00620022
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Torrance, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 3, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Axatilimab, Ruxolitinib, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD

NCT05607719
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Bevespi, Bretzri
Drug
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 3, 2026, 6:56 PM EDT